Evidence map›Paper›PMID 20862287›Full record

ArticlePloS one2010

Functional variant in complement C3 gene promoter and genetic susceptibility to temporal lobe epilepsy and febrile seizures.

Sarah Jamali, Annick Salzmann, Nader Perroud, Magali Ponsole-Lenfant, Jennifer Cillario, Patrice Roll, Nathalie Roeckel-Trevisiol, Ariel Crespel, Jorg Balzar, Kurt Schlachter and 7 more

Registry-linked trialOpen access · goldAbstract read
In one paragraph

Article in PloS one, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05450822 (The BrainDrugs-Epilepsy Study), which is not on this map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
1.1field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05450822 recruitingnot on this mapstarted 2022, after this paper: background citation

The BrainDrugs-Epilepsy Study: A Prospective Open-label Cohort Precision Medicine Study in Epilepsy

TypeobservationalSponsorGitte Moos KnudsenRan2022 to 2031Enrolled550ConditionsEpilepsyArmsLevetiracetam, Levetiracetam Tablets, Lamotrigine tablet
3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 34 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Review
  6. Aberrant Complement System Activation in Neurological Disorders.International journal of molecular sciences · 2021
    Review
  7. Insights into Potential Targets for Therapeutic Intervention in Epilepsy.International journal of molecular sciences · 2020
    Review
  8. Review
  9. Review
  10. Article
  11. Review
  12. Analysis of ComplementFrontiers in immunology · 2017
    Article
  13. Genetics of temporal lobe epilepsy: a review.Epilepsy research and treatment · 2012
    Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 7 institutions in 3 countries.

Sarah JamaliINSERM UMR 910, University of Méditerranée, Marseille, France.
Annick Salzmann
Nader Perroud
Magali Ponsole-Lenfant
Jennifer Cillario
Patrice Roll
Nathalie Roeckel-Trevisiol
Ariel Crespel
Jorg Balzar
Kurt Schlachter
Ursula Gruber-Sedlmayr
Ekaterina Pataraia
Christoph Baumgartner
Alexander Zimprich
Fritz Zimprich
Alain Malafosse
Pierre Szepetowski
Inserm · FRMedical University of Vienna · ATUniversity Hospital of Geneva · CHInstitut de Neurobiologie de la Méditerranée · FRCentre Hospitalier Universitaire de Montpellier · FRKlinik Hietzing · ATMedical University of Graz · AT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHuman mesial temporal lobe epilepsies (MTLE) represent the most frequent form of partial epilepsies and are frequently preceded by febrile seizures (FS) in infancy and early childhood. Genetic associations of several complement genes including its central component C3 with disorders of the central nervous system, and the existence of C3 dysregulation in the epilepsies and in the MTLE particularly, make it the C3 gene a good candidate for human MTLE. METHODOLOGY/PRINCIPAL

findingsA case-control association study of the C3 gene was performed in a first series of 122 patients with MTLE and 196 controls. Four haplotypes (HAP1 to 4) comprising GF100472, a newly discovered dinucleotide repeat polymorphism [(CA)8 to (CA)15] in the C3 promoter region showed significant association after Bonferroni correction, in the subgroup of MTLE patients having a personal history of FS (MTLE-FS+). Replication analysis in independent patients and controls confirmed that the rare HAP4 haplotype comprising the minimal length allele of GF100472 [(CA)8], protected against MTLE-FS+. A fifth haplotype (HAP5) with medium-size (CA)11 allele of GF100472 displayed four times higher frequency in controls than in the first cohort of MTLE-FS+ and showed a protective effect against FS through a high statistical significance in an independent population of 97 pure FS. Consistently, (CA)11 allele by its own protected against pure FS in a second group of 148 FS patients. Reporter gene assays showed that GF100472 significantly influenced C3 promoter activity (the higher the number of repeats, the lower the transcriptional activity). Taken together, the consistent genetic data and the functional analysis presented here indicate that a newly-identified and functional polymorphism in the promoter of the complement C3 gene might participate in the genetic susceptibility to human MTLE with a history of FS, and to pure FS. CONCLUSIONS/SIGNIFICANCE: The present study provides important data suggesting for the first time the involvement of the complement system in the genetic susceptibility to epileptic seizures and to epilepsy.

Indexed as

Genetic Predisposition to DiseasePromoter Regions, GeneticAdolescentCase-Control StudiesChildChild, PreschoolComplement C3Epilepsy, Temporal LobeFemaleGenetic VariationHumansMaleMicrosatellite RepeatsPolymorphism, Single NucleotideSeizures, FebrileYoung AdultComplement C3

Identifiers

PMID20862287
PMCPMC2940893
OpenAlexW2052995322

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.